Hepatic Oncostatin M Receptor β Regulates Obesity-Induced Steatosis and Insulin Resistance

Perry, 2014, The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes, Nature, 510, 84, 10.1038/nature13478 Birkenfeld, 2014, Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes, Hepatology, 59, 713, 10.1002/hep.26672 Glass, 2012, Inflammation and lipid signaling in the etiology of insulin resistance, Cell Metab, 15, 635, 10.1016/j.cmet.2012.04.001 Samuel, 2012, Mechanisms for insulin resistance: common threads and missing links, Cell, 148, 852, 10.1016/j.cell.2012.02.017 Berlanga, 2014, Molecular pathways in non-alcoholic fatty liver disease, Clin Exp Gastroenterol, 7, 221 Yoon, 2014, Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease, World J Hepatol, 6, 800, 10.4254/wjh.v6.i11.800 Wang, 2013, Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice, Hepatology, 58, 603, 10.1002/hep.26368 Wang, 2014, Interferon regulatory factor 3 constrains IKKbeta/NF-kappaB signaling to alleviate hepatic steatosis and insulin resistance, Hepatology, 59, 870, 10.1002/hep.26751 Inoue, 2004, Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo, Nat Med, 10, 168, 10.1038/nm980 Richards, 2013, The enigmatic cytokine oncostatin m and roles in disease, ISRN Inflamm, 2013, 512103, 10.1155/2013/512103 Richards, 1992, Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro, J Immunol, 148, 1731, 10.4049/jimmunol.148.6.1731 Chung, 2010, Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone, FASEB J, 24, 2093, 10.1096/fj.09-152561 Miyajima, 2000, Role of Oncostatin M in hematopoiesis and liver development, Cytokine Growth Factor Rev, 11, 177, 10.1016/S1359-6101(00)00003-4 Yamashita, 2010, Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation, Cancer Res, 70, 4687, 10.1158/0008-5472.CAN-09-4210 Han, 2013, JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation, Science, 339, 218, 10.1126/science.1227568 Priceman, 2013, Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance, Proc Natl Acad Sci U S A, 110, 13079, 10.1073/pnas.1311557110 Grove, 1991, Oncostatin M up-regulates low density lipoprotein receptors in HepG2 cells by a novel mechanism, J Biol Chem, 266, 18194, 10.1016/S0021-9258(18)55254-6 Henkel, 2011, Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis, Lab Invest, 91, 1107, 10.1038/labinvest.2011.47 Komori, 2014, Deficiency of oncostatin M receptor beta (OSMRbeta) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice, J Biol Chem, 289, 13821, 10.1074/jbc.M113.542399 Komori, 2013, Lack of oncostatin M receptor beta leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype, J Biol Chem, 288, 21861, 10.1074/jbc.M113.461905 Li, 2015, Tollip is a critical mediator of cerebral ischaemia/reperfusion injury, J Pathol, 237, 249, 10.1002/path.4565 Gomez-Lechon, 2007, A human hepatocellular in vitro model to investigate steatosis, Chem Biol Interact, 165, 106, 10.1016/j.cbi.2006.11.004 Zhu, 2014, Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor alpha in mice, J Hepatol, 60, 1046, 10.1016/j.jhep.2014.01.011 Hebbard, 2011, Animal models of nonalcoholic fatty liver disease, Nat Rev Gastroenterol Hepatol, 8, 35, 10.1038/nrgastro.2010.191 Tilg, 2010, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, Hepatology, 52, 1836, 10.1002/hep.24001 Cai, 2005, Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB, Nat Med, 11, 183, 10.1038/nm1166 Gual, 2005, Positive and negative regulation of insulin signaling through IRS-1 phosphorylation, Biochimie, 87, 99, 10.1016/j.biochi.2004.10.019 Blanchard, 2001, Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms, J Biol Chem, 276, 47038, 10.1074/jbc.M107971200 Caffarel, 2014, Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma, J Pathol, 232, 386, 10.1002/path.4305 Elks, 2015, Oncostatin m modulation of lipid storage, Biology (Basel), 4, 151 Chen, 2004, Oncostatin M: a pleiotropic cytokine in the central nervous system, Cytokine Growth Factor Rev, 15, 379, 10.1016/j.cytogfr.2004.06.002 Drechsler, 2012, Characterization of the rat oncostatin M receptor complex which resembles the human, but differs from the murine cytokine receptor, PLoS One, 7, e43155, 10.1371/journal.pone.0043155 Znoyko, 2005, Expression of oncostatin M and its receptors in normal and cirrhotic human liver, J Hepatol, 43, 893, 10.1016/j.jhep.2005.04.020 Matsumoto, 2006, Interleukin-6 and STAT3 protect the liver from hepatic ischemia and reperfusion injury during ischemic preconditioning, Surgery, 140, 793, 10.1016/j.surg.2006.04.010 Debonera, 2001, Activation of interleukin-6/STAT3 and liver regeneration following transplantation, J Surg Res, 96, 289, 10.1006/jsre.2001.6086 He, 2011, NF-kappaB and STAT3 - key players in liver inflammation and cancer, Cell Res, 21, 159, 10.1038/cr.2010.183